Over 200 drugs under development, top 50 with $30 billion potential: Cipla

Spelling out the company's target for the North American business, Cipla said it plans to maintain momentum of filing 10 to 15 abbreviated new drug applications (ANDAs) per year and emphasise on limited competition opportunities.

It said the aim is to grow it "from current 8 per cent to 20-25 per cent of overall sales by 2020".

In the fiscal year ending March 31, Cipla had total income from operations of Rs 11,345.44 crore.

In order to expand the business in North America, Cipla said it has "levers in place to achieve successful transition from pure B2B to Direct plus B2B model in the US, backed by our capabilities in respiratory, HIV and oncology".

The firm said it will also leverage key partner relationships for launch of first-to-market and differentiated generics products such as Esomeprazole, Dymista Nasal Spray, Budesonide Respules, Escitalopram and Finasteride.

The company said it also plans to strengthen organic presence in North American market to drive success to Cipla label products and to launch differentiated respiratory and oncology pipeline in near future.

It is also planning to launch the product pipeline of Invagen post acquisition completion and realise synergies, it added. Cipla in September had announced entering into an agreement to acquire US-based InvaGen Pharmaceuticals for $500 million.